Biodegradable polymeric iodine contrast agents for CT angiography.

用于 CT 血管造影的可生物降解的聚合碘造影剂。

• 批准号: 8455343
• 负责人: VISHWAS N JOSHI
• 金额: $ 24.25万
• 依托单位: NANOPROBES, INC.
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-04-01 至 2016-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8455343
• 关键词: Acute; Affect; Angiography; Animals; Antibodies; Aorta; Arterial Fatty Streak; Biocompatible; Biodistribution; Biological; Blood; Brain Death; Brain Injuries; Carbonates; Cardiac; Cessation of life; Characteristics; Contrast Media; Coronary; Coronary Arteriosclerosis; Coronary artery; Country; Development; Diagnosis; Diagnostic; Dose; Electrocardiogram; Emergency Situation; Emulsions; Event; FDA approved; Gadolinium; Gold; Half-Life; Healed; Heart failure; Hemorrhage; Hospitalization; Hyaluronic Acid; Image; Imagery; Immune response; Infection; Inflammation; Injection of therapeutic agent; Injury; Intervention; Iodine; Ischemia; Isovue; Kidney; Label; Legal patent; Link; Lipids; Liver; Low Dose Radiation; Magnetic Resonance Imaging; Measurement; Measures; Molecular Target; Multimodal Imaging; Myocardium; Nature; Neoplasm Metastasis; New Agents; Noise; Obesity; Obstruction; Organ; Osmolalities; Patients; Performance; Pharmaceutical Preparations; Polyesters; Polyglycolic Acid; Polymers; Preparation; Prevalence; Process; Radiation; Reducing Agents; Resolution; Risk; Risk Factors; Roentgen Rays; Rupture; Scanning; Site; Slice; Solutions; Source; Spasm; Spleen; Stenosis; Techniques; Time; Tissues; Toxic effect; Tube; Vertebral column; Work; X-Ray Computed Tomography; acute coronary syndrome; angiogenesis; attenuation; base; detector; diagnosis standard; diagnostic accuracy; gadolinium oxide; healing; hemodynamics; in vivo; iron oxide; monomer; nephrotoxicity; novel; poly(lactide); polycarbonate; prospective; public health relevance; repaired; response; screening; stability testing; tumor; voltage; Acute; Affect; Angiography; Animals; Antibodies; Aorta; Arterial Fatty Streak; Biocompatible; Biodistribution; Biological; Blood; Brain Death; Brain Injuries; Carbonates; Cardiac; Cessation of life; Characteristics; Contrast Media; Coronary; Coronary Arteriosclerosis; Coronary artery; Country; Development; Diagnosis; Diagnostic; Dose; Electrocardiogram; Emergency Situation; Emulsions; Event; FDA approved; Gadolinium; Gold; Half-Life; Healed; Heart failure; Hemorrhage; Hospitalization; Hyaluronic Acid; Image; Imagery; Immune response; Infection; Inflammation; Injection of therapeutic agent; Injury; Intervention; Iodine; Ischemia; Isovue; Kidney; Label; Legal patent; Link; Lipids; Liver; Low Dose Radiation; Magnetic Resonance Imaging; Measurement; Measures; Molecular Target; Multimodal Imaging; Myocardium; Nature; Neoplasm Metastasis; New Agents; Noise; Obesity; Obstruction; Organ; Osmolalities; Patients; Performance; Pharmaceutical Preparations; Polyesters; Polyglycolic Acid; Polymers; Preparation; Prevalence; Process; Radiation; Reducing Agents; Resolution; Risk; Risk Factors; Roentgen Rays; Rupture; Scanning; Site; Slice; Solutions; Source; Spasm; Spleen; Stenosis; Techniques; Time; Tissues; Toxic effect; Tube; Vertebral column; Work; X-Ray Computed Tomography; acute coronary syndrome; angiogenesis; attenuation; base; detector; diagnosis standard; diagnostic accuracy; gadolinium oxide; healing; hemodynamics; in vivo; iron oxide; monomer; nephrotoxicity; novel; poly(lactide); polycarbonate; prospective; public health relevance; repaired; response; screening; stability testing; tumor; voltage

DESCRIPTION (provided by applicant): Recent advances in micro-CT machines have made it possible to image with a resolution of <10 ¿m. Scans take ~6 to 20 minutes to acquire, and current iodine contrast agents due to their short half-lives are not generally suitable. We recentl commercialized non-toxic gold X-ray contrast agent, AuroVist", but they are lot more expensive than iodine agents and their whole body clearance is very slow. We now propose biodegradable polymeric contrast agents that are composed of FDA approved components: hyaluronic acid or polylactide/polyglycolide and a derivative of iodine agent Iobitridol that are lot cheaper than our gold-based contrast agents and more absorptive than conventional iodine agents. The new agents can be labeled with additional contrast agents, such as gadolinium or iron oxide, enabling multimodal imaging or double contrasting with dual-beam/dual-detector CT. When labeled with iodine agents and targeting molecules will enable in vivo visualization of organ function, angiogenesis, repair, tumor formation, metastasis, studies of response to drugs and other therapies or conditions, such as ischemia or radiation, and basic biological studies of animals including development, infection, immune response, cardiac studies, tissue injury and healing. The new contrast agents will provide more than four times the radiodensity as compared to the conventional iodine contrast agents and will enable longer imaging times as they are intravascular. These agents will more accurately identify vulnerable plaque by clearly identifying lipid core volume as a percentage of plaque volume, angiogenesis/inflammation, and stenoses, among other risk factors. In addition, their higher radiodensity will enable better imaging of obese patients, reduce radiation dose in normal sized patients and reduce nephrotoxicity to permit use in kidney compromised patients. These capabilities go beyond what other agents offer and if clinically implemented could, through screening, reduce the prevalence of coronary artery disease deaths.

描述（由应用程序提供）：Micro-CT机器的最新进展使得可以以<10€m的分辨率进行映像。扫描需要约6到20分钟才能获取，并且由于其短半衰期而导致的当前碘对比剂通常不合适。 We recently commercialized non-toxic gold X-ray contrast agent, AuroVist", but they are many more expensive than iodine agents and their whole body clearance is very slow. We now propose biodegradable polymeric contrast agents that are composed of FDA approved components: hyaluronic acid or polylactide/polyglycolide and a derivative of iodine agent Iobitridol that are lot cheaper than our 基于黄金的对比剂和吸收性比常规碘剂更吸收。新代理可以用其他造影剂标记，例如gadolinium或氧化铁，从而实现多模式成像或与双光束/双探测器CT的双重对比。当用碘剂和靶向分子标记时，将实现器官功能，血管生成，修复，肿瘤形成，转移，对药物和其他疗法或其他条件的研究（例如缺血或辐射）的研究，以及对动物的基本生物学研究以及包括发育，感染，感染，ImmunoreSpse，心脏，心脏损伤，组织，组织，组织和治愈的基本生物学研究。与常规的碘对比剂相比，新的对比剂将提供超过四倍的放射剂，并且由于血管内而启用更长的成像时间。这些药物将通过清楚地将脂质核心体积识别为斑块体积的百分比，血管生成/炎症和狭窄以及其他危险因素，从而更准确地识别易受攻击的斑块。此外，它们的较高的放射态度将使肥胖患者更好地成像，减少正常大小的患者的放射剂量，并降低肾毒性，以允许在肾脏受损的患者中使用。这些能力超出了其他代理商所提供的功能，如果通过筛查临床实施，可以降低冠状动脉疾病死亡的患病率。